Cefixime (CAS 79350-37-1) is a third-generation oral cephalosporin antibiotic widely prescribed for respiratory tract infections, urinary tract infections, and otitis media . With a global market size valued at approximately $783 million in 2024 and projected to exceed $1 billion by 2032, cefixime remains one of the most clinically significant oral antibiotics worldwide . The compound functions by inhibiting bacterial cell wall synthesis through high-affinity binding to penicillin-binding proteins, demonstrating broad-spectrum activity against Gram-negative bacteria, including strains resistant to earlier cephalosporins . Available in multiple dosage forms including tablets (200mg, 400mg), capsules, and oral suspensions, cefixime serves both hospital and primary healthcare settings. Understanding the global buyers list is essential for API suppliers,…